The Ichilov Clinic is widely known for its innovative approaches in medical research. Access to the latest advancements in oncology and hematology ensures the effectiveness of treatment for Mu (μ) heavy chain disease in Israel and the chances of a positive prognosis. In Israel, qualified hematologists, oncologists, and other specialists work who have trained and practiced in leading medical institutions worldwide.
At the Ichilov Clinic, great attention is paid to the individual needs of each patient, offering the most suitable methods of diagnosis and treatment. The medical center is equipped with the latest medical technologies, allowing for accurate diagnostics and effective treatment under the guidance of multidisciplinary teams of specialists. Patients in Israel can access the latest treatment methods that are not yet available in other countries.
The medical center provides assistance with medical and organizational issues. It offers support services, translation, and coordination, taking into account the cultural and religious needs of patients.
About the Disease
Heavy chain diseases are tumor pathologies of plasma cells characterized by abnormal production of heavy chains of monoclonal immunoglobulins. The first physician to describe heavy chain disease in 1963 was Dr. E. S. Franklin. A year later, four more patients treated by E. F. Osserman and K. Takatsuki were diagnosed with similar symptoms, and the term "heavy chain disease" emerged. Currently, heavy chain diseases of alpha [α] IgA, gamma [γ] IgG, and mu [μ] IgM have been described.
The Mu (μ) heavy chain disease (IgM heavy chain disease, mu chain disease) is extremely rare. In most plasma cell disorders, the monoclonal immunoglobulin protein is structurally similar to normal antibody molecules, but in heavy chain pathologies, the body produces defective immunoglobulins – incomplete paraproteins. They lack the components of light chains and contain only fragments of the heavy chain.
The causes of the disease are unknown. Scientists believe that structural genetic mutations lead to a failure in the deletion program of variable length heavy chains.
The symptoms of mu chain disease mimic the clinical picture of chronic lymphocytic leukemia and other lymphoproliferative disorders. The pathology is most commonly diagnosed in adults over 50 years old. The most frequent and characteristic signs are lesions of visceral organs – spleen, liver, abdominal lymph nodes.
Send your records — an Ichilov physician will reply within 1–2 days, free of charge.
Treatment Methods for the Disease
IgM heavy chain disease is a rare condition, and there is no unified approach to its treatment. Therapy aims to control symptoms and suppress the abnormal cloning of immune cells. Each treatment plan is strictly individualized and promptly adjusted based on the stage of the disease, the overall health of the patient, and their response to therapy. Doctors at the Ichilov Clinic conduct continuous monitoring of treatment response and adapt the course for maximum effect and minimization of possible side effects.
A team of specialists is involved in the diagnosis and development of a treatment plan for IgM heavy chain disease, including: a hematologist, oncologist, immunologist, infectious disease specialist, radiologist, endoscopist, transplantologist, geneticist or molecular biologist, and other physicians.
The multidisciplinary team allows for a comprehensive assessment of the disease and the development of the most effective treatment strategy, considering all aspects of the specific case.
Chemotherapy
Cyclic chemotherapy is used to reduce the level of monoclonal proteins in the blood and decrease the number of affected cells. This method is considered part of a comprehensive treatment plan and varies depending on the stage of the disease, overall health status, and disease progression characteristics.
Doctors may choose one or a combination of drugs most suitable for treatment. Chemotherapeutic agents can be administered intravenously via infusion or in tablet form, depending on the specific drug and treatment regimen. Procedures are conducted in cycles, combining periods of treatment and rest, allowing the body to recover while maximizing the destruction of malignant cells.
Treatment with Monoclonal Antibodies
Treatment with monoclonal antibodies is a type of biological therapy that uses specially designed antibodies to recognize and selectively destroy specific molecules on the surface of cancer cells. These antibodies are created using biotechnological methods to interact with specific antigens (proteins). These antibodies are monoclonal – identical and directed at the same target molecule.
They can trigger the immune system against the target, block growth signals, preventing tumor growth, or deliver radioactive particles or toxins directly to cancer cells. Their specificity allows them to attack specific cancer cells while minimizing impact on healthy cells and tissues, making the procedure less toxic compared to traditional chemotherapy.
The use of monoclonal antibodies in the treatment of Mu (μ) heavy chain disease is particularly effective when standard approaches do not yield the desired results or when the cancer is specific and sensitive to particular biological treatments.
Alkylating Agent-Based Therapy
Alkylating agents are a class of chemotherapeutic drugs used to treat various types of cancer. These substances act on cells by damaging their DNA, thereby preventing replication and causing cell death. Alkylating agents chemically react with DNA molecules in cancer cells. The alkyl group attaches to DNA to bind its strands or alkylate individual bases, preventing normal DNA replication and initiating apoptosis (programmed cell death).
There are several different alkylating agents, and the doctor selects the most appropriate one based on the type and stage of the disease.
Corticosteroids
Treatment with corticosteroids is based on drugs derived from corticosteroid hormones, naturally produced by the adrenal cortex. They affect various processes in the body, including immune responses, inflammation, metabolism, and maintenance of electrolyte homeostasis.
Depending on the severity of the condition, different types of corticosteroids are used, and the dosage and duration of treatment can vary significantly. In many cases, the dosage of corticosteroids is increased until the desired effect is achieved, and then gradually reduced for a safe conclusion of the course.
Stem Cell Transplantation
Stem cell transplantation may be used as a treatment method for IgM Heavy Chain Disease when standard treatments are ineffective or the disease is rapidly progressing. The procedure is considered if the patient experiences relapses after chemotherapy or other types of treatment, including the use of monoclonal antibodies, chemotherapeutic agents, or alkylating drugs.
Stem cell transplants are performed in two ways:
- autologous, involving the collection of the patient's own stem cells before the start of intensive chemotherapy or radiation and their freezing. Intensive methods destroy cancerous cells in the bone marrow, after which the preserved healthy stem cells are returned to the patient's body.
- allogeneic, involving the transplantation of stem cells from a donor.
Targeted Therapy
Targeted therapy for Mu (μ) heavy chain disease uses drugs specifically aimed at certain molecular targets present in cancer cells. Unlike chemotherapy, which attacks all rapidly dividing cells, targeted therapy aims to more selectively affect cancer cells with minimal impact on healthy tissues.
The effectiveness of targeted therapy and the improvement of patients' quality of life compared to traditional treatment methods make it a promising area in oncology, especially for complex and rare cases such as mu chain disease.
- Stem Cell Treatment
- Chemotherapy
Diagnosis Methods for the Disease
The symptoms of mu chain disease may overlap with other lymphoproliferative disorders. The goal of a comprehensive study is not only to confirm the diagnosis of Mu (μ) heavy chain disease but also to exclude other similar pathologies, assess the overall condition of the patient, and determine the stage of the disease, which is critically important for planning treatment and prognosis.
The diagnosis of IgM heavy chain disease includes a series of laboratory and instrumental studies aimed at identifying characteristic signs of the disease. Most often, a bone marrow examination is required to clarify the diagnosis.
First Day
The doctor discusses the patient's symptoms and medical history. A physical examination is conducted, during which signs of enlarged lymph nodes, liver, or spleen changes are sought.
Second Day
Laboratory Blood Tests
- Complete blood count and biochemical tests help detect anemia, changes in protein levels, and other disorders that may indicate the presence of a hematological disease.
- Serological studies to determine the amount of immunoglobulins and the presence of paraprotein.
- Immunoelectrophoresis of serum or immunofixation to identify abnormal immunoglobulins.
- The monoclonality of heavy chains IgM can be confirmed by immunohistochemistry or flow cytometry methods.
Urine tests, including for the presence of Bence-Jones protein.
Instrumental Studies
- Abdominal ultrasound, CT, or MRI to assess the size of internal organs and detect signs of lymph nodes.
- Endoscopic studies for visualizing mucosal changes.
Biopsy with histopathological examination
- Examination of tissues from lymph nodes, bone marrow, or other affected areas with subsequent histological analysis to determine the nature of the cellular composition.
- Immunophenotyping, often with flow cytometry or immunohistochemistry to determine the monoclonality of heavy chains.
Molecular genetic studies to identify specific genetic abnormalities associated with various hematological diseases.
Third Day
The peculiarity of IgM heavy chain disease is its similarity to the symptoms of other conditions. At the Ichilov Clinic, practical experience has been gained in diagnosing this complex and rare disease. The doctors at the medical center are skilled in accurately interpreting the results of serum protein electrophoresis and know how to distinguish mu chain disease (IgM) from anemia, leukopenia, thrombocytopenia, eosinophilia, and pathologies of circulating atypical lymphocytes and plasma cells.
- Computed Tomography
- Magnetic Resonance Imaging (MRI)
- Ultrasound
- Biopsy and Histological Studies
- Blood Biochemistry
How Much Does Treatment Cost
The cost of therapy at the Ichilov Clinic can vary significantly from case to case. The price depends on the patient's condition at the time of entering the medical center, the stage of the disease, and the number and complexity of diagnostic and therapeutic procedures.
A professional medical coordinator will clarify all your questions. You can call and find out where to find reviews and ratings of doctors and departments, ask any questions via online chat or feedback form on the website.
Advantages of Treating Mu (μ) Heavy Chain Disease at the Ichilov Clinic in Israel
- High level of medical expertise
- Personalized approach to the patient
- Use of modern technologies and a multidisciplinary team of doctors
- Access to the latest developments in the treatment of tumor pathologies of plasma cells
- Logistical and language support
Make your choice of clinic for treatment based on reliable factors. At Ichilov, an experienced medical team is ready to assist patients. Patients at this medical center can expect high-quality medical care and support at every stage of the diagnostic and treatment process. You can request a video call via Zoom or Skype and receive a consultation from a specialist with clinical experience in treating this complex and rare disease.